Medpace (MEDP) Stock Price & Analysis
Score
AI Analysis
SnapshotMedpace Holdings is a mixed profile at 49/100 — Value 18, Growth 60, Quality 68. Under the hood: P/E 35.8, plus revenue compounding ~20% annually over recent years.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Medpace Holdings, Inc. (MEDP) last printed $610.54. Equity value is $17.08B. Trailing earnings multiple 34.25. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $421.58M | $436.15M | $704.59M | $860.97M | $925.92M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
About
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.